THE PROGNOSTIC-SIGNIFICANCE OF IMMUNE CHANGES IN PATIENTS WITH RENAL-CELL CARCINOMA TREATED WITH INTERFERON-ALFA-2B

被引：25

作者：

KOSMIDIS, PA ^{[1
]}

BAXEVANIS, CN ^{[1
]}

TSAVARIS, N ^{[1
]}

PAPANASTASIOU, M ^{[1
]}

ANASTASOPOULOS, E ^{[1
]}

BACOYIANNIS, C ^{[1
]}

MYLONAKIS, N ^{[1
]}

KARVOUNIS, N ^{[1
]}

BAFALOUKOS, D ^{[1
]}

KARABELIS, A ^{[1
]}

PAPAMICHAIL, M ^{[1
]}

机构：

[1] HELLEN ANTICANC INST,DEPT IMMUNOL,ATHENS,GREECE

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1992年 / 10卷 / 07期

关键词：

D O I：

10.1200/JCO.1992.10.7.1153

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To evaluate the response rate and the immunorestorative properties of subcutaneously administered interferon alfa-2b (IFN-A2b) in patients with advanced renal cell carcinoma (RCC) and to correlate the immune status with the clinical responses. Patients and Methods: Twenty-six patients with advanced RCC were treated with recombinant IFN-A2b. The dose was increased progressively from 5 x 106 IU the first week to 10 x 106 IU the second week, and thereafter to 15 x 106 IU subcutaneously. Results: Four patients (15%) achieved partial responses (PRs), and five patients (19%) had stable disease (S), whereas 17 patients (65%) progressed. In all patients, blood was withdrawn before IFN treatment and monthly thereafter. T lymphocytes after isolation from peripheral blood were tested for proliferation in the autologous mixed lymphocyte reaction (autoMLR) and allogeneic mixed lymphocyte reaction (alloMLR), interleukin-2 (IL-2) production, expression of IL-2 receptors during the alloMLR, and the production of interleukin-1 (IL-1) by peripheral-blood monocytes. Twelve patients were assessable, four patients had a PR, one patient had S, and seven patients had progressive disease. Striking increases were demonstrated in all parameters 1 month after treatment with IFN-A2b in the four patients who responded and the patient with S. Namely, the autoMLR responses showed a mean increase of 250%, the IL-2 production 247%, the expression of IL-2- specific receptors 446%, the alloMLR responses 160%, and the production of IL-1 262%. On the contrary, the nonresponders did not show any change in their overall immune status, and in some, deterioration of the already depressed immunologic functions was observed. Conclusions: Administration of IFN-A2b results in a marked potentiation of deficient cellular immune response in vitro in those patients with RCC who respond to the treatment. This may have prognostic significance, and certainly more patients are required to be studied for definite conclusions.

引用

页码：1153 / 1157

页数：5

共 28 条

[21]

RODRIGUEZ MA, 1983, J IMMUNOL, V130, P1215

[22]

SHIRAKAWA F, 1985, J IMMUNOL, V134, P3560

[23] IMMUNOLOGICAL STUDIES IN CHRONIC LYMPHOCYTIC-LEUKEMIA - DEFECTIVE STIMULATION OF T-CELL PROLIFERATION IN AUTOLOGOUS MIXED LYMPHOCYTE CULTURE [J].